Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action

Cinthia Farina, Martin S. Weber, Edgar Meinl, Hartmut Wekerle, Reinhard Hohlfeld

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Glatiramer acetate is a synthetic random copolymer approved for the immunomodulatory therapy of relapsing-type multiple sclerosis (MS). Previous work has focused on the effects of this drug on T cells, especially the glatiramer-acetate-induced shift of the cytokine profile towards those characteristic of T-helper-2 (Th2) cells. Glatiramer acetate was thought to bring about this Th2 shift by acting like an altered peptide ligand but more recent work has shown that the drug notably affects the properties of antigen-presenting cells, such as monocytes and dendritic cells. These new observations might offer an explanation for the previously observed Th2 shift. In this review, we focus on these new findings. We address several controversial issues, including the possible neurotrophic effects of glatiramer acetate, the potential role of neutralising antibodies to the drug, and attempts to develop biomarkers of the treatment response. Finally, we will think about how a better understanding of glatiramer acetate might help the development of new immunomodulatory agents for MS.

Original languageEnglish
Pages (from-to)567-575
Number of pages9
JournalThe Lancet Neurology
Volume4
Issue number9
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Action Potentials
Multiple Sclerosis
Pharmaceutical Preparations
Th2 Cells
Immunomodulation
Antigen-Presenting Cells
Neutralizing Antibodies
Dendritic Cells
Monocytes
Biomarkers
Glatiramer Acetate
Cytokines
Ligands
T-Lymphocytes
Peptides
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Glatiramer acetate in multiple sclerosis : Update on potential mechanisms of action. / Farina, Cinthia; Weber, Martin S.; Meinl, Edgar; Wekerle, Hartmut; Hohlfeld, Reinhard.

In: The Lancet Neurology, Vol. 4, No. 9, 09.2005, p. 567-575.

Research output: Contribution to journalArticle

Farina, Cinthia ; Weber, Martin S. ; Meinl, Edgar ; Wekerle, Hartmut ; Hohlfeld, Reinhard. / Glatiramer acetate in multiple sclerosis : Update on potential mechanisms of action. In: The Lancet Neurology. 2005 ; Vol. 4, No. 9. pp. 567-575.
@article{218116146af14dfe8570b91e622a8c25,
title = "Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action",
abstract = "Glatiramer acetate is a synthetic random copolymer approved for the immunomodulatory therapy of relapsing-type multiple sclerosis (MS). Previous work has focused on the effects of this drug on T cells, especially the glatiramer-acetate-induced shift of the cytokine profile towards those characteristic of T-helper-2 (Th2) cells. Glatiramer acetate was thought to bring about this Th2 shift by acting like an altered peptide ligand but more recent work has shown that the drug notably affects the properties of antigen-presenting cells, such as monocytes and dendritic cells. These new observations might offer an explanation for the previously observed Th2 shift. In this review, we focus on these new findings. We address several controversial issues, including the possible neurotrophic effects of glatiramer acetate, the potential role of neutralising antibodies to the drug, and attempts to develop biomarkers of the treatment response. Finally, we will think about how a better understanding of glatiramer acetate might help the development of new immunomodulatory agents for MS.",
author = "Cinthia Farina and Weber, {Martin S.} and Edgar Meinl and Hartmut Wekerle and Reinhard Hohlfeld",
year = "2005",
month = "9",
doi = "10.1016/S1474-4422(05)70167-8",
language = "English",
volume = "4",
pages = "567--575",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Glatiramer acetate in multiple sclerosis

T2 - Update on potential mechanisms of action

AU - Farina, Cinthia

AU - Weber, Martin S.

AU - Meinl, Edgar

AU - Wekerle, Hartmut

AU - Hohlfeld, Reinhard

PY - 2005/9

Y1 - 2005/9

N2 - Glatiramer acetate is a synthetic random copolymer approved for the immunomodulatory therapy of relapsing-type multiple sclerosis (MS). Previous work has focused on the effects of this drug on T cells, especially the glatiramer-acetate-induced shift of the cytokine profile towards those characteristic of T-helper-2 (Th2) cells. Glatiramer acetate was thought to bring about this Th2 shift by acting like an altered peptide ligand but more recent work has shown that the drug notably affects the properties of antigen-presenting cells, such as monocytes and dendritic cells. These new observations might offer an explanation for the previously observed Th2 shift. In this review, we focus on these new findings. We address several controversial issues, including the possible neurotrophic effects of glatiramer acetate, the potential role of neutralising antibodies to the drug, and attempts to develop biomarkers of the treatment response. Finally, we will think about how a better understanding of glatiramer acetate might help the development of new immunomodulatory agents for MS.

AB - Glatiramer acetate is a synthetic random copolymer approved for the immunomodulatory therapy of relapsing-type multiple sclerosis (MS). Previous work has focused on the effects of this drug on T cells, especially the glatiramer-acetate-induced shift of the cytokine profile towards those characteristic of T-helper-2 (Th2) cells. Glatiramer acetate was thought to bring about this Th2 shift by acting like an altered peptide ligand but more recent work has shown that the drug notably affects the properties of antigen-presenting cells, such as monocytes and dendritic cells. These new observations might offer an explanation for the previously observed Th2 shift. In this review, we focus on these new findings. We address several controversial issues, including the possible neurotrophic effects of glatiramer acetate, the potential role of neutralising antibodies to the drug, and attempts to develop biomarkers of the treatment response. Finally, we will think about how a better understanding of glatiramer acetate might help the development of new immunomodulatory agents for MS.

UR - http://www.scopus.com/inward/record.url?scp=23744480760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744480760&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(05)70167-8

DO - 10.1016/S1474-4422(05)70167-8

M3 - Article

C2 - 16109363

AN - SCOPUS:23744480760

VL - 4

SP - 567

EP - 575

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 9

ER -